Large, Anionic Liposomes Enable Targeted Intraperitoneal Delivery of a TLR 7/8 Agonist To Repolarize Ovarian Tumors’ Microenvironment

Specific targeting of ovarian tumor-associated macrophages by large, anionic nanoparticles

(2020) Tom Haber et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

High-capacity poly(2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive, metastatic model of lung adenocarcinoma

(2020) Natasha Vinod et al.   Science Advances

Tumor‐associated macrophage‐targeted therapeutics in ovarian cancer

(2020) Yuanyuan An et al.   INTERNATIONAL JOURNAL OF CANCER

Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study

(2019) U A Matulonis et al.   ANNALS OF ONCOLOGY

Drug-free mannosylated liposomes inhibit tumor growth by promoting the polarization of tumor-associated macrophages

(2019) Jun Ye et al.   International Journal of Nanomedicine

Targeting Tumor-Associated Macrophages in Cancer

(2019) Paulina Pathria et al.   TRENDS IN IMMUNOLOGY

Lyophilizable and Multifaceted Toll-like Receptor 7/8 Agonist-Loaded Nanoemulsion for the Reprogramming of Tumor Microenvironments and Enhanced Cancer Immunotherapy

(2019) Sun-Young Kim et al.   ACS Nano

Ovarian cancer statistics, 2018

(2018) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations

(2018) Jun Gong et al.   Journal for ImmunoTherapy of Cancer

TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy

(2018) Christopher B. Rodell et al.   Nature Biomedical Engineering

Amphiphilic nanoparticle delivery enhances the anticancer efficacy of a TLR7 ligand via local immune activation

(2018) Inès Mottas et al.   BIOMATERIALS

A pilot clinical trial testing topical resiquimod and a xenopeptide as immune adjuvants for a melanoma vaccine targeting MART-1

(2018) Matthew S. Block et al.   MELANOMA RESEARCH

Liposomal Formulations in Clinical Use: An Updated Review

(2017) Upendra Bulbake et al.   Pharmaceutics

QuPath: Open source software for digital pathology image analysis

(2017) Peter Bankhead et al.   Scientific Reports

Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer

(2016) Mingzhu Yin et al.   JOURNAL OF CLINICAL INVESTIGATION

Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer

(2015) Junzo Hamanishi et al.   JOURNAL OF CLINICAL ONCOLOGY

Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination in Patients with High-Risk Melanoma

(2015) R. L. Sabado et al.   Cancer Immunology Research

Tumor-Associated Macrophages: From Mechanisms to Therapy

(2014) Roy Noy et al.   IMMUNITY

Liposomes in tissue engineering and regenerative medicine

(2014) N. Monteiro et al.   Journal of the Royal Society Interface

Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: Correlation of CD163 expression, cytokine levels and early relapse

(2013) Silke Reinartz et al.   INTERNATIONAL JOURNAL OF CANCER

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2010) N. Colombo et al.   ANNALS OF ONCOLOGY

Involvement of M2-polarized macrophages in the ascites from advanced epithelial ovarian carcinoma in tumor progression via Stat3 activation

(2010) Kiyomi Takaishi et al.   CANCER SCIENCE

Peritoneal retention of liposomes: Effects of lipid composition, PEG coating and liposome charge

(2010) S. Dadashzadeh et al.   JOURNAL OF CONTROLLED RELEASE

Liposome drugs' loading efficiency: A working model based on loading conditions and drug's physicochemical properties

(2009) Daniel Zucker et al.   JOURNAL OF CONTROLLED RELEASE